Aura Biosciences (NASDAQ:AURA) Announces Quarterly Earnings Results, Beats Expectations By $0.08 EPS

Aura Biosciences (NASDAQ:AURA) posted its earnings results on Monday. The company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.37) by $0.08, FiscalAI reports.

Aura Biosciences Stock Performance

Shares of Aura Biosciences stock opened at $7.66 on Tuesday. Aura Biosciences has a twelve month low of $4.73 and a twelve month high of $9.53. The business has a 50-day moving average price of $6.54 and a 200 day moving average price of $6.73.

Analysts Set New Price Targets

A number of research analysts have issued reports on the company. HC Wainwright decreased their price target on Aura Biosciences from $24.00 to $18.00 and set a “buy” rating for the company in a report on Tuesday, August 11th. Citigroup reaffirmed a “market outperform” rating on shares of Aura Biosciences in a research note on Tuesday. Wall Street Zen lowered shares of Aura Biosciences from a “hold” rating to a “sell” rating in a report on Sunday, August 16th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Aura Biosciences in a research note on Monday, October 12th. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $17.50.

Aura Biosciences Company Profile

Aura Biosciences, Inc (NASDAQ:AURA) is a clinical-stage biotechnology company developing targeted therapies for cancer. The company’s platform is designed to use tumor-targeting virus-like particles to selectively bind to cancer cells and deliver therapeutic payloads, with the goal of treating tumors while limiting damage to surrounding healthy tissue.

Aura’s lead product candidate is AU-011, also known as belzupacap sarotalocan, an investigational therapy being developed for primary choroidal melanoma, a form of eye cancer.